

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GOCABR

Page 1 of 1

DOCTOR	'S ORDERS Htcm Wt	kg BSAm²
REMINDER: I	Please ensure drug allergies and previous bleomycin a	are documented on the Allergy & Alert Form
DATE:	To be given:	Cycle #:
Date of Previous Cycle:		
☐ CBC & Dif	ment week(s) f day of treatment with doses as written, if within 72 hours ANC greater than 0 x 10 ⁹ /L	or equal to 1.5 x 10 ⁹ /L, Platelets <u>greater than</u>
Dose modification for:		
Proceed with treatment based on blood work from		
AND select ONE of the following:	TIONS: Patient to take own supply. RN/Pharmacist to come □ 8 mg or □ 12 mg (select one) PO 30 to 60 minutes □ ondansetron 8 mg PO 30 to 60 minutes prior to CA aprepitant 125 mg PO 30 to 60 minutes prior to CA ondansetron 8 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CA netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to 60 minutes prior to 60 mg PO 30 to 60 mi	ARBOplatin ARBOplatin, and ARBOplatin
If additional antiemetic required: ☐ OLANZapine ☐ 2.5 mg or ☐ 5 mg or ☐ 10 mg (select one) PO 30 to 60 minutes prior to CARBOplatin☐ Other:		
** Have Hypersensitivity Reaction Medications and Protocol Available**		
TREATMENT: PACLitaxel NAB (ABRAXANE) 260 mg/m² x BSA =mg Dose Modification:% =mg IV over 30 minutes (in empty sterile PVC, non-PVC or non-DEHP bag and tubing; use tubing with 15 micron filter) CARBOplatin AUC 6 or 5 (circle one) x (GFR + 25) =mg Dose Modification:% =mg IV in 100 to 250mL NS over 30 minutes.		
RETURN APPOINTMENT ORDERS		
	nree weeks, or ☐ four weeks for Doctor and Cycle nent. Return in week(s).	·
If indicated: CE Prior to next cy total bilirul CA 15-3 Refer to He Other tests Consults:	eatinine prior to next cycle. CC & Diff on Day 14 and/or Day 21. Ccle, if clinically indicated: Din Alkaline phosphatase GGT ALT CA 125 CA 19-9 CEA SCC Pereditary Cancer Program (see accompanying referral contents:	form)
DOCTOR'S	SIGNATURE:	SIGNATURE: UC: